Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives $18.75 Consensus Price Target from Analysts

Posted by Geri Gentry on Sep 5th, 2026

Shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the seven analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $18.75.

KLRS has been the topic of a number of recent research reports. Wedbush began coverage on Kalaris Therapeutics in a research note on Thursday, May 14th. They issued an “outperform” rating and a $17.00 target price on the stock. Citizens Jmp dropped their price objective on shares of Kalaris Therapeutics from $26.00 to $25.00 and set a “market outperform” rating on the stock in a report on Wednesday, May 13th. Weiss Ratings downgraded shares of Kalaris Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 28th. TD Cowen started coverage on shares of Kalaris Therapeutics in a research note on Monday, June 15th. They set a “buy” rating for the company. Finally, Citigroup restated an “outperform” rating on shares of Kalaris Therapeutics in a research report on Wednesday, May 13th.

View Our Latest Stock Analysis on KLRS

Kalaris Therapeutics Trading Down 1.0%

Shares of NASDAQ KLRS opened at $3.90 on Monday. The company has a market cap of $92.86 million, a price-to-earnings ratio of -1.93 and a beta of 0.22. Kalaris Therapeutics has a 12-month low of $3.03 and a 12-month high of $11.88. The stock’s 50 day simple moving average is $4.13 and its 200 day simple moving average is $5.60.

Kalaris Therapeutics (NASDAQ:KLRS – Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.02. As a group, equities analysts forecast that Kalaris Therapeutics will post -1.99 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kalaris Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Nano Cap New Millennium Growth Fund L P acquired a new stake in Kalaris Therapeutics in the 4th quarter valued at approximately $34,000. Sigma Planning Corp acquired a new position in Kalaris Therapeutics during the 2nd quarter worth $41,000. Barclays PLC acquired a new position in Kalaris Therapeutics during the 4th quarter worth $51,000. Johnson Financial Group Inc. bought a new position in shares of Kalaris Therapeutics in the third quarter worth $58,000. Finally, XTX Topco Ltd bought a new position in shares of Kalaris Therapeutics in the second quarter worth $65,000. 66.05% of the stock is owned by institutional investors.

Kalaris Therapeutics Company Profile

(Get Free Report)

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.